


**REMARKS**

The subject case is a PCT application entering the US National Phase under 35 U.S.C. § 371 and Article 39(1)(a) of the Patent Cooperation Treaty.

Claims 17 and 19-29 are cancelled. Claim 30 is amended by insertion of the phrase "or a pharmaceutically acceptable salt thereof," which is used throughout the application and claims and is therefore well supported.

Applicants respectfully request substantive examination of the claims. If the Examiner wishes to discuss any matter relating to this application, the Examiner is invited to telephone the undersigned attorney at the number below.

Respectfully submitted,

By   
James L. McGinnis  
Reg. No. 34,387  
Attorney for Applicant

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-0641

Date: January 25, 2005